Parmax Pharma [PARMAX] vs Divi's Laboratories [DIVISLAB] Detailed Stock Comparison

Parmax Pharma Ltd.

BSE
Loading...

Divi's Laboratories Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Parmax Pharma Ltd. wins in 3 metrics, Divi's Laboratories Ltd. wins in 14 metrics, with 0 ties. Divi's Laboratories Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Parmax Pharma Ltd. Divi's Laboratories Ltd. Better
P/E Ratio (TTM) -5.63 67.11 Divi's Laboratories Ltd.
Price-to-Book Ratio -2.43 10.82 Divi's Laboratories Ltd.
Debt-to-Equity Ratio -2.38 0.58 Divi's Laboratories Ltd.
PEG Ratio -0.06 4.63 Divi's Laboratories Ltd.
EV/EBITDA 109.78 48.63 Divi's Laboratories Ltd.
Profit Margin (TTM) 15.84% 24.04% Divi's Laboratories Ltd.
Operating Margin (TTM) -6.82% 29.65% Divi's Laboratories Ltd.
EBITDA Margin (TTM) N/A 29.65% N/A
Return on Equity 105.30% 14.64% Parmax Pharma Ltd.
Return on Assets (TTM) -11.17% 12.94% Divi's Laboratories Ltd.
Free Cash Flow (TTM) $-16.59M $2.15B Divi's Laboratories Ltd.
Dividend Yield N/A 0.91% N/A
1-Year Return -18.44% 0.83% Divi's Laboratories Ltd.
Price-to-Sales Ratio (TTM) 0.42 16.18 Parmax Pharma Ltd.
Enterprise Value $197.87M $1,635.46B Divi's Laboratories Ltd.
EV/Revenue Ratio 0.70 15.86 Parmax Pharma Ltd.
Gross Profit Margin (TTM) 28.35% 63.71% Divi's Laboratories Ltd.
Revenue per Share (TTM) $75 $388 Divi's Laboratories Ltd.
Earnings per Share (Diluted) $-13.55 $93.66 Divi's Laboratories Ltd.
Beta (Stock Volatility) N/A 0.19 N/A

Parmax Pharma Ltd. vs Divi's Laboratories Ltd. Stock Performance Analysis

Loading Price Chart...

PARMAX
DIVISLAB

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Parmax Pharma Ltd.-10.44%37.89%57.11%56.72%48.13%51.69%
Divi's Laboratories Ltd.0.40%-2.96%-0.35%4.44%1.97%3.98%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Parmax Pharma Ltd.-18.44%19.45%-36.21%196.24%196.24%196.24%
Divi's Laboratories Ltd.0.83%89.86%56.44%484.44%1,625.50%9,907.51%

Performance & Financial Health Analysis: Parmax Pharma Ltd. vs Divi's Laboratories Ltd.

MetricPARMAXDIVISLAB
Market Information
Market Cap i₹117.89M₹1.69T
Market Cap CategorySmall capLarge cap
10 Day Avg. Volume i391253,443
90 Day Avg. Volume i664283,911
Last Close₹45.73₹6,623.00
52 Week Range₹22.60 - ₹53.38₹5,636.50 - ₹7,071.50
% from 52W High-14.33%-6.34%
All-Time High₹81.90 (Jun 14, 2021)₹7,071.50 (Jul 08, 2025)
% from All-Time High-44.16%-6.34%
Growth Metrics
Quarterly Revenue Growth0.71%0.12%
Quarterly Earnings Growth-0.31%-0.01%
Financial Health
Profit Margin (TTM) i0.16%0.24%
Operating Margin (TTM) i-0.07%0.30%
Return on Equity (TTM) i1.05%0.15%
Debt to Equity (MRQ) i-2.380.58
Cash & Liquidity
Book Value per Share (MRQ)₹-12.94₹580.95
Cash per Share (MRQ)N/A₹122.95
Operating Cash Flow (TTM) i₹-20,488,477₹19.67B
Levered Free Cash Flow (TTM) i₹-20,940,101₹21.91B
Dividends
Last 12-Month Dividend Yield iN/A0.91%
Last 12-Month Dividend iN/A₹60.00

Valuation & Enterprise Metrics Analysis: Parmax Pharma Ltd. vs Divi's Laboratories Ltd.

MetricPARMAX (Apr 24, 2026)DIVISLAB (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-5.6367.11
Forward P/E iN/A53.75
PEG Ratio i-0.064.63
Price to Sales (TTM) i0.4216.18
Price to Book (MRQ) i-2.4310.82
Market Capitalization
Market Capitalization i₹117.89M₹1.69T
Enterprise Value i₹197.87M₹1.64T
Enterprise Value Metrics
Enterprise to Revenue i0.7015.86
Enterprise to EBITDA i109.7848.63
Risk & Other Metrics
Beta iN/A0.19
Book Value per Share (MRQ) i₹-12.94₹580.95

Financial Statements Comparison: Parmax Pharma Ltd. vs Divi's Laboratories Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPARMAX (2025)DIVISLAB (2025)
Revenue/Sales i282.04M93.25B
Cost of Goods Sold i237.36M38.70B
COGS % of Revenue i84.2%41.5%
Gross Profit i44.68M54.55B
Gross Margin i15.8%58.5%
Research & Development iN/A270.00M
Operating Income (EBIT) i-7.77M25.71B
Operating Margin i-2.8%27.6%
EBITDA i1.80M33.19B
EBITDA Margin i0.6%35.6%
Pre-Tax Income i-23.95M29.16B
Pre-Tax Income % of Revenue i-8.5%31.3%
Income Tax i-3.01M7.25B
Income Tax % of Revenue i-1.1%7.8%
Net Income (Profit) i-20.94M21.91B
Profit Margin i-7.4%23.5%

Balance Sheet & Liquidity Metrics

MetricPARMAX (2025)DIVISLAB (2025)
Cash & Equivalents i903,2794.15B
Total Current Assets i100.03M100.81B
Total Current Assets % of Revenue i35.5%108.1%
Total Current Liabilities i130.37M14.52B
Total Current Liabilities % of Revenue i46.2%15.6%
Long-Term Debt i77.04M20.00M
Long-Term Debt % of Revenue i27.3%0.0%
Total Shareholders Equity i-19.89M149.69B
Retained Earnings i-64.40M134.00B
Retained Earnings % of Revenue i-22.8%143.7%
Property, Plant & Equipment i17.29M3.19B

Cash Flow Statement Comparison

MetricPARMAX (2025)DIVISLAB (2025)
Operating Cash Flow i-20.49M19.67B
Operating Cash Flow % of Revenue i-7.3%21.1%
Capital Expenditures i-7.01M-14.38B
Free Cash Flow i-16.59M2.15B
FCF Margin i-5.9%2.3%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPARMAXDIVISLAB
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i3.74M265.47M
Float Shares iN/A117.72M
% Held by Insiders i64.25%52.04%
% Held by Institutions i0.00%28.65%
% Held by Public i35.75%19.31%

Dividend Analysis & Yield Comparison: Parmax Pharma Ltd. vs Divi's Laboratories Ltd.

MetricPARMAXDIVISLAB
Last 12-Month Dividend iN/A₹60.00
Last 12-Month Dividend Yield iN/A0.91%
3-Year Avg Annual Dividend iN/A₹50.00
3-Year Avg Dividend Yield iN/A0.70%
3-Year Total Dividends iN/A₹150.00
Ex-Dividend DateN/AJul 25, 2025